Sichuan Kelun Pharmaceutical Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
Sichuan Kelun Pharmaceutical Co., Ltd. carries a market capitalization of 53.37B, placing it among publicly traded companies globally. Its enterprise value stands at 59.34B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 53.37B |
| Enterprise Value | 59.34B |
Share Statistics
Sichuan Kelun Pharmaceutical Co., Ltd. currently has 1.60B shares outstanding.
| Shares Outstanding | 1.60B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Sichuan Kelun Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 26.55. The price-to-sales ratio is 2.97, and the price-to-book ratio stands at 4.23.
| PE Ratio | 26.55 |
| PS Ratio | 2.97 |
| PB Ratio | 4.23 |
| P/TBV Ratio | 2.08 |
| P/FCF Ratio | 36.89 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Sichuan Kelun Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 19.53 and an EV/FCF ratio of 36.41. The EV/Sales ratio of 3.11 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 19.53 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.11 |
| EV / EBITDA | 19.53 |
| EV / EBIT | 19.53 |
| EV / FCF | 36.41 |
Financial Position
Sichuan Kelun Pharmaceutical Co., Ltd. maintains a current ratio of 2.16, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 16.38, indicating elevated leverage, while an interest coverage ratio of 26.22 demonstrates strong ability to service its debt obligations.
| Current Ratio | 2.16 |
| Quick Ratio | 0.78 |
| Debt / Equity | 16.38 |
| Debt / EBITDA | 1.55 |
| Interest Coverage | 26.22 |
Financial Efficiency
Sichuan Kelun Pharmaceutical Co., Ltd. posts a return on equity of 16.38 and a return on invested capital of 7.45.
| Return on Equity (ROE) | 16.38 |
| Return on Assets (ROA) | 5.54 |
| Return on Invested Capital (ROIC) | 7.45 |
| Return on Capital Employed (ROCE) | 9.38 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.83 |
Taxes
Over the trailing twelve months, Sichuan Kelun Pharmaceutical Co., Ltd. has paid 577.91M in income taxes, reflecting an effective tax rate of 20.36.
| Income Tax | 577.91M |
| Effective Tax Rate | 20.36 |
Stock Price Statistics
Sichuan Kelun Pharmaceutical Co., Ltd.'s stock has declined approximately -12.17277% over the past 52 weeks. The 50-day moving average sits at 34.08, while the 200-day moving average is 33.75.
| Beta (5Y) | N/A |
| 52-Week Price Change | -12.17277% |
| 50-Day Moving Average | 34.08 |
| 200-Day Moving Average | 33.75 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Sichuan Kelun Pharmaceutical Co., Ltd. generated 19.07B in revenue and converted that into 2.14B in net income, yielding earnings per share of 1.43. EBITDA reached 3.04B, while operating income came in at 3.04B.
| Revenue | 19.07B |
| Gross Profit | 9.43B |
| Operating Income | 3.04B |
| Pretax Income | 2.84B |
| Net Income | 2.14B |
| EBITDA | 3.04B |
| EBIT | 3.04B |
| Earnings Per Share (EPS) | 1.43 |
Balance Sheet
Sichuan Kelun Pharmaceutical Co., Ltd. holds 7.06B in cash and equivalents against 4.69B in total debt, resulting in a net debt position of -2.42B. Total book value stands at 13.40B, with working capital of 10.51B providing operational flexibility.
| Cash & Cash Equivalents | 7.06B |
| Total Debt | 4.69B |
| Net Debt | -2.42B |
| Equity (Book Value) | 13.40B |
| Book Value Per Share | 8.49 |
| Working Capital | 10.51B |
Cash Flow
After subtracting -1.54B in capital expenditures, free cash flow totaled -1.54B - equivalent to -0.97 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -1.54B |
| Free Cash Flow | -1.54B |
| FCF Per Share | -0.97 |
Margins
Sichuan Kelun Pharmaceutical Co., Ltd. operates with a gross margin of 49.44, reflecting its pricing power and cost economics. The operating margin of 15.93 and net profit margin of 11.20 provide insight into operational efficiency.
| Gross Margin | 49.44 |
| Operating Margin | 15.93 |
| Pretax Margin | 14.88 |
| Profit Margin | 11.20 |
| EBITDA Margin | 15.93 |
Dividends & Yields
The company's payout ratio of 55.30 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.83 |
| Dividend Yield | N/A |
| Payout Ratio | 55.30 |
| Shareholder Yield | 2.21 |
| FCF Yield | 2.71 |
Stock Splits
Sichuan Kelun Pharmaceutical Co., Ltd.'s most recent stock split took place on July 22, 2015 with a 1:2 split ratio.
| Last Split Date | 7/22/2015 |
| Split Ratio | 1:2 |
Scores
Sichuan Kelun Pharmaceutical Co., Ltd. posts an Altman Z-Score of 4.82, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.82 |